Adicet Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $48.68M
- P/E (TTM)
- –
- Dividend yield
- –
About Adicet Bio
Pharmaceutical Preparations, SIC 2834
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company utilizes donor-derived peripheral blood cells to engineer "off-the-shelf" chimeric antigen receptor (CAR) therapies intended to facilitate durable clinical activity without triggering graft-versus-host immune responses. Its clinical-stage pipeline is led by prulacabtagene leucel (prula-cel), a CAR T cell product targeting CD20 under evaluation for various autoimmune indications, including lupus nephritis, systemic lupus erythematosus, and systemic sclerosis. Additionally, the company advances preclinical programs such as ADI-212, which targets prostate-specific membrane antigen for solid tumors.
Adicet Bio operates as a single segment focused on the development of its biopharmaceutical platform and product pipeline. The company conducts research and clinical development activities domestically within the United States and maintains research relationships in China. Its principal executive offices and headquarters are located in Boston, Massachusetts.
Summary of the business section of Adicet Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Adicet Bio, Inc.
- Headquarters
- Boston, MA
- Address
- 131 Dartmouth Street, 3rd Floor 02116
- Phone
- (617) 482-2333
- Website
- adicetbio.com
- Employees
- 102, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 26
- Auditor
- KPMG LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ACET
- Exchange
- Nasdaq
- IPO date
- Jan 29, 2018
- Shares outstanding
- 9M, Aug 3, 2026
- Public float
- $50.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-16 reverse, Mar 12, 2026; 1-for-16 reverse, Dec 30, 2025; 1-for-16.67 reverse, Nov 5, 2020; 1-for-7 reverse, Sep 16, 2020
- SEC CIK
- 1720580
- CUSIP
- 007002207
- ISIN
- US0070022076
- LEI
- 549300VRD2QO80WBOP18
- EIN
- 81-3305277
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lloyd Klickstein | Chief Medical Officer, Director | 108,566 |
| Chen Schor | President & CEO, Director | 10,159 |
| Blake Aftab | Chief Scientific Officer | 2,981 |
| Julia D. Maltzman | Chief Medical Officer | – |
| Brian Nicholas Harvey | Chief Financial Officer | 5,145 |
| Don Healey | Chief Technology Officer | 3,452 |
| Andrew Sinclair | Director | 2,133,085 |
| Jeffrey Chodakewitz | Director | 17,700 |
| Michael Grissinger | Director | – |
| Katie Peng | Director | 11,800 |
| Steve Dubin | Director | 22,700 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Chen Schor | $1.47M | $347.82K | $1.02M | $6 | – |
| FY2024 Chen Schor | $4.64M | $2.55M | $1.61M | $11 | – |
| FY2023 Chen Schor | $5.97B | -$498.11M | $2.11M | $21 | – |
| FY2022 Chen Schor | $3.99B | -$3.56B | $2.23M | $45 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 102 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 7, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 11, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 1, 2020 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Sep 30, 2020 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Sep 18, 2020 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 16, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Aug 21, 2020 | Name change | Name changed from resTORbio, Inc. to Adicet Bio, Inc. |
| Jun 23, 2020 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Jan 29, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 22, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |